Abstract
Introduction
Extracorporeal membrane oxygenation (ECMO) is a supportive intensive-care technique to counteract acute reversible cardiorespiratory failure. ECMO provides prolonged cardiopulmonary bypass while allowing the lungs to rest using minimal ventilator settings (1) . A trial in critically ill neonates conferred a survival advantage of ECMO over conventional management -except in cases of congenital diaphragmatic hernia (CDH) -without a concomitant increase in severe disability (2) .
Sensorineural hearing loss (SNHL) is one of the disabilities reported in patients who have undergone ECMO-treatment (3) (4) (5) . It was found in 28 of 371 ECMO-survivors (7.5%) from 6 different centers in North America (6) , Frequencies per center ranged from 3 to 21%; follow-up from 1-10 years. Several groups have reported delayed onset of SNHL and therefore advocated ongoing follow-up testing (4, 5, 7) . A number of risk factors for SNHL after neonatal intensive care have been identified: presence of CDH (7), prolonged ventilatory support (8, 9) prolonged ECMO (7, 10) , sepsis or bacterial meningitis (8, 11) , prolonged administration of aminoglycosides (7), severe birth asphyxia (9, 11) , cerebral bleeding or cerebral infarction (11) , and clinical seizures prior to ECMO treatment (10) .
Infants with hearing loss (HL) are at risk for delayed speech development and language acquisition, impaired academic achievement, and social/ emotional developmental problems (12, 13) . Early identification of HL and appropriate intervention could prevent or minimize adverse effects on these developmental areas (14, 15) . To our knowledge only one study -by Desai et al. -explored the relationship between hearing loss and language development of ECMO survivors; the relationship between neonatal brainstem audiometry results and delayed receptive language ability proved uncertain (16) . To shed more light on this issue we tested hearing as well as speech-and language development in survivors of neonatal ECMO-treatment. The following research questions were addressed: 1) What is the prevalence of SNHL after neonatal ECMO treatment?; 2) Does HL affect speech-and language development and intelligence?
Participants and methods

Participants
A cohort of children, now aged between 5 and 12 years, who had received neonatal veno-arterial (VA) ECMO support between January 1992 and February 2005, and mainly consisting of children living in the referral area of the Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands l. The large majority had been treated in this hospital an additional four in the Radboud University Nijmegen Medical Center (Nijmegen, the Netherlands), and one in the University Hospitals Leuven (Leuven, Belgium). Inclusion criteria and treatment protocols did not differ between these centers. ECMO was initiated in case of reversible severe respiratory failure and an estimated mortality risk of higher than 80% using the entry criteria reported by Stolar et al. (17) .
Entry criteria and exclusion criteria were previously described by our group (18) and did not change during the study period. Cerebral ultrasound examinations were performed prior to treatment with ECMO, daily during ECMO treatment, and before discharge from our hospital. All subjects of the study reported here participate in a prospective post-ECMO follow-up program that provides for regular assessments of lung function, growth and developmental parameters until 18 years of age (19) . Based on the national consensus on neonatal follow-up and the Dutch Ministry of Health's requirement to provide relevant data, the assessment protocol is the standard of care following ECMO treatment. As a consequence IRB approval was waived. Parents of all children studied were informed about the study and gave written informed consent to evaluate data collected during routine care.
Procedures and study design
The following clinical characteristics were recorded prospectively: underlying condition, gestational age, birth weight, age at onset of ECMO, duration of ECMO support, mean airway pressure (MAP) and highest oxygenation index (OI) prior to ECMO, duration of mechanical ventilation before ECMO, total duration of mechanical ventilation (including ECMO), duration of oxygen dependency, and prevalence of chronic lung disease (CLD). CLD was defined as oxygen dependency at day 28 (20) . are substantially related to each other (22) . The BSID-II-NL was administered to 8 children.
At 5 years of age the Reynell Test (receptive language development), the Schlichting Test (syntactical and lexical expression), and the short version of the Revised Amsterdam Intelligence Test were administered to assess language development and intelligence, as described previously (19) .
Data analysis Hearing assessment
In consultation with the audiologist (A.G.) the audiograms were interpreted as follows. Two frequency bands were distinguished: low and high. For the low frequency band the mean HL was calculated at 500, 1000 and 2000 kHz; for the high frequency band at 2000, 4000 and 8000 kHz. HL severity was categorized in terms of clinical consequences. HL <20 dB is "not significant", thus "normal"; 20-40 dB is "mild"; and >40 dB is "moderate to severe". HL was considered symmetrical if it was of the same category in both ears for both frequencies.
We distinguished between "conductive HL" (>10 dB difference between the bone conduction response and the air conduction response) and "SNHL only" (difference ≤10 dB). If both were present HL was labelled as: combined. Tympanometry was used to confirm conductive HL.
Language development and intelligence
Language developmental and intelligence scores below 85 (<-1 SD) were categorized as "below average"; scores between 85 and 115 (≥ -1 SD and ≤ +1 SD) as "average"; and scores above 115 (>+1 SD) as "above average".
Statistical methods
Group comparisons were tested with the Kruskal-Wallis H test. The Mann-Whitney test with Bonferroni correction was used for post-hoc analysis. Proportions were compared using the Chi-square test. Data on HL and developmental tests for two subgroups -underlying condition CDH or meconium aspiration syndrome (MAS) -were analyzed separately. These two subgroups were considered of special interest. CDH is associated with abnormal lung development with severe pulmonary hypertension and increased prevalence of HL (7, 23, 24) ; infants with MAS form the largest homogeneous subgroup of children treated with ECMO. The other subgroups are small and more heterogeneous with respect to underlying disease. Data are presented as mean (SD) or median (range). Statistical significance was accepted at a two-sided 5% level for all tests. Statistical analyses were performed using SPSS 17.0 for Windows.
Results
Between January 1992 and February 2005 a total of 257 neonates received ECMO in our center and 5 children from our referral area elsewhere; 76 patients died at neonatal age (29%; CDH n=46 (61%)).
Of the remaining patients, 34 did not participate in the follow-up program (parents' refusal n=17; other reasons n=17), and 13 did not undergo audiometry for different reasons (Figure 1) . One of them, a girl who had suffered from severe birth asphyxia, had been diagnosed with severe bilateral SNHL at the age of 6 months and wore hearing aids. She was evaluated elsewhere. Two other children who had been evaluated elsewhere had normal hearing. In 8 others who were not tested (7 for practical reasons and 1 with Down syndrome and ENT follow-up elsewhere) HL was not suspected by members of the follow-up team or the parents. Information on HL was lacking in the 2 remaining children: One was suffering from mental retardation and autism and lacked cognitive ability for audiometry; one, seen at age 5 years before audiometry was introduced into our program, had died of multiple congenital anomalies before the next scheduled visit.
Thus, 139 children underwent audiometry. We excluded the results of three 5-year-old participants because they could not be tested reliably (Figure 1) . Therefore, the results of 136 children were analyzed; 104 of them (76%) were tested at age 5 years, 20 (15%) at 8 years, and 12 (9%) at 12 years.
Data on language development and intelligence at age 5 years had not been obtained in 28 children born before 1996 (because the follow-up program started in 2001) and in two 5-year-olds born after 1996 (due to parental refusal). Thus, developmental evaluation at 5 years was performed in 106 children (audiometry in 104 because in 2 of them audiometry was performed at 8 years); for 66 of these children developmental data at 2 years were also available. The Reynell receptive language development test and the Schlichting subtests for syntactical and lexical development were not administered to 17 children (practical reasons n=10; poor cognitive competence n=3; insufficient command of the Dutch language n=3; and language development tested elsewhere n=1). Of these 17 children, 12 had normal hearing, 2 had moderate to severe unilateral HL (one sensorineural and one conductive), 1 had mild conductive unilateral HL and 2 had mild conductive bilateral HL. For 7 children tested at 5 years a reliable intelligence score could not be calculated (poor cognitive competence n=5; recent assessment elsewhere with intelligence within normal range n=1; assessment with non-verbal test due to hearing problems with intelligence in normal range n=1). 18 (13) 14 (10) Chronic lung disease, n(%) no yes unknown 100 (74) 27 (20) 9 (7) CDH = congenital diaphragmatic hernia; MAS = meconium aspiration syndrome; remaining diagnoses consist of: persistent pulmonary hypertension n=18, sepsis n=8, pneumonia n=4, birth asphyxia n=2, cardiac disease n=2, other n=3. Chronic lung disease was defined as oxygen dependency at day 28.
The baseline characteristics of all participants are shown in Five children had bilateral SNHL (3.7% of the study population); in 2 of them (1.5%) SNHL was mild, symmetrical, and of high frequencies only. Three children (2.2%) had moderate to severe bilateral SNHL, symmetrical in 2 of them, with loss of both high and low frequencies. The characteristics of these 5 children are described in Table 2 . All had normal cerebral ultrasound during ECMO treatment. SNHL in the remaining 7 children (5.1%) was unilateral; in 2 children it had resolved at follow-up. In 2 of the other 5 it was mild, but 3 children (2.2% of the study population) had completely impaired hearing in one ear (ipsilateral cerebral infarction n=1; bacterial meningitis at age 1 month n=1; unknown cause n=1). All three had abnormal audiological examinations within the first months of life and HL had been diagnosed early. The patient with bacterial meningitis suffered from severe combined HL. Table 3 .
At 5 years of age the median language and intelligence scores were in the normal range (Table 3) .
Receptive language development, syntactical language expression and lexical language expression did not differ between children with normal hearing, mild hearing loss, and moderate to severe hearing loss (p=0.800, p=0.639, p=0.876, respectively; Kruskal-Wallis H-test). The same was true for intelligence (p=0.886; Kruskal-Wallis H-test). Table 3 Developmental results at 2 and 5 years following neonatal ECMO
years
Verbal score (n=66)
Mild hearing loss (n=13)
Moderate to severe hearing loss (n=5)
Normal hearing (n=48)
Non-verbal score (n=66)
Reynell (n=89) Mild hearing loss (n=18)
Moderate to severe hearing loss (n=4)
Normal hearing (n=67)
Schlichting syntactical language expression (n=89)
Mild hearing loss (n=18)
Schlichting lexical language expression (n=89)
Mild hearing loss (n= 18)
Intelligence quotient (n=99)
Mild hearing loss (n=20)
Normal hearing (n=74)
Discussion
In this study we found that 75.7% of children had normal hearing 5 to 12 years after neonatal VA-ECMO treatment; 15.4% of children had conductive HL. SNHL was established in 12 of the 136 children (8.8%). SNHL was bilateral in 5 (3.7%); three of them wore hearing aids and/or received special audiological care (2.2% of the total sample). Overall, the children's language development and intelligence at 2 and 5 years were normal. Language development and intelligence results of children with HL were not worse than those of children with normal hearing.
Few epidemiologic data on hearing impairment in the normal pediatric population are available. In the United States it is estimated to occur in 1.1 per 1000 infants (25); a study in the Netherlands found that 0.78 per 1000 infants had permanent hearing impairment (13) . Recently, Cone and co-workers reported a 0.88% prevalence of SNHL in primary school-aged children (26) . In 2009, Mehra and coworkers concluded from audiometric screening studies that 3.1% of children and adolescents in the United States suffer from unilateral or bilateral hearing impairment (>20 dB). Those screening studies took place between 1958 and 1993 and most children were between 6 and 19 years old (25) . We found an eightfold higher prevalence of HL (24.3%), mainly of conductive origin. A high prevalence of conductive HL within the first 24 months of life has been reported in very low birth weight infants, especially in those with chronic lung disease (up to 54.5%) (27) . Nasally-placed tubes for ventilatory assistance and disturbed local immunity might be associated with chronic otitis media with effusion in infants up to two years of age (28) . Although all of our patients had been ventilated neonatally, it is unclear whether nasal tube placement and discturbed immunity explain our results at the age of 5 years, because our population was not born prematurely and the prevalence of conductive HL seems to decrease with age. Another possible explanation is that the 5-year-old children in our study may have suffered from recurrent respiratory tract infections with concomitant conductive HL. However, all these assumptions are speculative and do not seem to fully explain the discrepancy in findings.
Further evaluation by ENT-surgeons will be needed to uncover the origin and clinical course of conductive HL in ECMO-treated patients.
Regarding SNHL, Cheung and Robertson (6) reported a 7.5% overall prevalence of SNHL in ECMO survivors, ranging from 3 to 21% in six different ECMO centers in the United States. All reviewed studies had been published before 1996. Fligor and co-workers found a 26% prevalence of bilateral SNHL in ECMO survivors born between 1986 and 1994 (7) . Almost half of the children had delayedonset SNHL, and 72% had progressive HL. Cheung and co-workers also reported normal clinical neonatal screening results in children who developed SNHL. The prevalence of bilateral SNHL in our population is in accordance with data published on larger series in the United States (29, 30) . One child with severe bilateral SNHL, who would have been eligible for the follow-up program, was evaluated elsewhere and her data had been excluded from our analysis. Should we have included her data, the prevalence of SNHL would have been 9.5% (13 of 137 cases) with bilateral HL in 4.4% (6 of 137 children).
In our study neonatal screening data were not available for 3 of 5 children with bilateral SNHL. One child failed to pass the neonatal screening and was referred for audiological care at an early stage. In one child who passed the neonatal screening test successfully, SNHL was diagnosed at 13 months, indicating delayed-onset SNHL.
A high prevalence of SNHL has been reported in children with CDH, even those not treated with ECMO (7, 23, 24) . Two of the 24 CDH patients in our study had mild SNHL (one patient with bilateral HL also had a partial chromosome X duplication). Similarly, Morando and co-workers (31) reported one patient with SNHL in a cohort of 26 CDH survivors not treated with ECMO. CDH is not the only risk factor for SNHL after ECMO treatment. Other reported factors are: treatment with aminoglycosides (7, 32) , furosemide, muscle relaxants (32), initiation of ECMO-treatment after >160
hours (7), prolonged ECMO treatment, and pre-ECMO seizures(10) A nationwide study in the Netherlands revealed that the only independent risk factors for HL in neonates receiving intensive care
were severe birth asphyxia and assisted ventilation for ≥5 days (9) . The small number of children with bilateral SNHL in the present study did not allow for multivariate analysis. Yet, all 5 patients with bilateral SNHL had between 2 and 5 of the above-mentioned risk factors.
All our patients were treated with VA-ECMO. During this procedure deoxygenated blood is removed from the right internal jugular vein and oxygenated blood is returned through a cannula placed in the right carotid artery. Veno-venous (VV) ECMO is a technique that has now gained more acceptancealso in our institution -for use in patients with an isolated pulmonary disease without the need for cardiac support (33) . Using this technique, the carotid artery need not be sacrificed and the normal pulsatility to the systemic flow is maintained. The risk for central nervous system complications (bleeding, microthrombi or infarct) seems to be less in VV-ECMO than in VA-ECMO (33 (35, 36) . It seems, therefore, to be important to detect HL at an early stage and provide early intervention.
For the main purpose of this study we described the characteristics of 5 children with purely bilateral SNHL (Table 2) . Interestingly, two with profound SNHL diagnosed at an early age (at 0.2 years and 1.1 years respectively; patients 3 and 4 in Table 2 ) and wearing hearing aids showed normal intelligence and language development. The other three children had been diagnosed later, and showed worse intelligence and language development. In all three, however, language development and/or intelligence might have been affected by comorbidity: Two had an underlying problem associated with impaired intelligence: severe birth asphyxia (patient 1; Table 2 ) and a partial duplication of chromosome X with mental retardation (patient 2; Table 2 ), respectively. The third was not a native Dutch speaker (patient 5; Table 2 ).
Conclusions
In 
